Smith & Nephew plc: Q4 and Full Year 2024 Results Summary
Business Context and Reporting Period
Company: Smith & Nephew plc (LSE: SN, NYSE: SNN)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fourth Quarter and Full Year ended December 31, 2024
Filing Date: February 25, 2025
Context: The global medical technology business reported results driven by its "12-Point Plan," focusing on revenue growth, margin expansion, and cash flow generation. The company operates in three primary segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Key Financial Metrics (Full Year 2024)
| Metric | 2024 ($m) | 2023 ($m) | Change (%) |
|---|---|---|---|
| Revenue | 5,810 | 5,549 | 4.7% (Reported) / 5.3% (Underlying) |
| Operating Profit | 657 | 425 | 54.6% |
| Operating Profit Margin | 11.3% | 7.7% | +360 bps |
| Trading Profit | 1,049 | 970 | 8.2% |
| Trading Profit Margin | 18.1% | 17.5% | +60 bps |
| Cash from Operations | 1,245 | 829 | 50.2% |
| Free Cash Flow | 551 | 129 | 327.1% |
| EPS (Basic) | 47.2 cents | 30.2 cents | 56.3% |
| EPSA (Adjusted) | 84.3 cents | 82.8 cents | 1.7% |
| Net Debt (excl. leases) | 2,513 | 2,577 | -2.5% |
| Adjusted Leverage Ratio | 1.9x | 2.1x | -0.2x |
Material Changes vs. Prior Period
- Revenue Growth: Underlying revenue grew 5.3% for the full year, driven by operational improvements and new product launches (over 60% of growth from products launched in the last 5 years). Reported growth was 4.7%, impacted by a -60bps foreign exchange headwind.
- Profitability: Operating profit surged 54.6% to $657 million, primarily due to a significant reduction in restructuring charges ($123 million in 2024 vs. $220 million in 2023) and margin expansion.
- Cash Flow: Free cash flow more than quadrupled to $551 million, driven by improved working capital discipline (Day Sales of Inventory reduced by 20 days) and lower capital expenditure.
- Segment Performance:
- Orthopaedics: Underlying growth of 4.6%. US Reconstruction showed sequential improvement (Knee +5.4%, Hip +7.6% in Q4).
- Sports Medicine & ENT: Underlying growth of 6.2%. Strong performance outside China (14.0% underlying growth in Q4) offset by Volume Based Procurement (VBP) headwinds in China.
- Advanced Wound Management: Underlying growth of 5.1%, with Advanced Wound Devices growing 12.2%.
- Restructuring: The company delivered a near 9% net reduction in total workforce over 2023-2024, with over 1,000 role reductions in 2024 alone.
Guidance, Outlook, and Risks
2025 Outlook:
- Revenue: Targeting underlying revenue growth of around 5% (reported growth ~4.8%). Q1 2025 underlying growth expected to be 1-2% due to China headwinds and one fewer trading day, with acceleration expected thereafter.
- Margins: Full year trading profit margin expected to range between 19.0% and 20.0%, representing a significant step-up. Margins expected to be stronger in H2 2025.
- Cash Flow: Trading cash conversion expected to be 80-90%. Restructuring costs expected to decrease to ~$45 million.
- Tax Rate: Forecast at 19-20% on trading results.
Management Commentary: CEO Deepak Nath stated the transformation is on track, with the 12-Point Plan delivering better financial performance. The company expects 2025 to be the year transformation unlocks substantial value for shareholders.
Risks and Contingencies:
- China Headwinds: Continued impact from Volume Based Procurement (VBP) in Reconstruction and Sports Medicine, with an estimated $25 million revenue headwind in 2025 from an extension into Arthroscopic Enabling Technologies.
- Legal: Ongoing metal-on-metal hip claims (provision reduced by $28 million in 2024).
- Macroeconomic: Inflation, foreign exchange volatility, and global economic conditions affecting healthcare spending.
Key Facts for Investor Verification
- China Exposure: Verify the specific timeline and magnitude of the VBP impact on Sports Medicine and Orthopaedics in 2025, as this is a primary drag on growth.
- Margin Sustainability: Confirm if the projected 19-20% trading margin in 2025 accounts for potential inflationary pressures on input costs and labor.
- Restructuring Completion: Monitor the reduction of restructuring costs to the guided $45 million in 2025 to ensure the "12-Point Plan" charges are concluding as expected.
- US Reconstruction Momentum: Validate the sequential improvement in US Hip and Knee implants, which was a key driver of Q4 strength.
- Dividend Policy: Note the total dividend of 37.5 cents per share (unchanged from 2023) and the target payout ratio of 35-40% of EPSA starting in 2025.